Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy H Goodship

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Opinion in Nephrology and Hypertension|December 20, 2007
Update on evaluating complement in hemolytic uremic syndromeDavid Kavanagh, Timothy H Goodship
Pediatric Nephrology (Berlin, Germany)|June 19, 2004
Challenges in the management of infantile factor H associated hemolytic uremic syndromeGuido Filler, Seetha Radhakrishnan, Lisa Strain, et al.
Pediatric Nephrology (Berlin, Germany)|April 30, 2013
Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor BRodney D Gilbert, Darren J Fowler, Elizabeth Angus, et al.
Clinical Kidney Journal|January 15, 2014
Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of <i>CD46</i> treated with eculizumabRodney D Gilbert, Louise K Stanley, Darren J Fowler, et al.
Kidney International|August 3, 2012
Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulationDanielle Paixão-Cavalcante, Margarita López-Trascasa, Lillemor Skattum, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 3, 2010
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotypeMarina Noris, Jessica Caprioli, Elena Bresin, et al.
Kidney International|July 29, 2017
Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and IrelandVicky Brocklebank, Sally Johnson, Thomas P Sheerin, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Opinion in Nephrology and Hypertension|December 20, 2007
Update on evaluating complement in hemolytic uremic syndromeDavid Kavanagh, Timothy H Goodship
Pediatric Nephrology (Berlin, Germany)|June 19, 2004
Challenges in the management of infantile factor H associated hemolytic uremic syndromeGuido Filler, Seetha Radhakrishnan, Lisa Strain, et al.
Pediatric Nephrology (Berlin, Germany)|April 30, 2013
Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor BRodney D Gilbert, Darren J Fowler, Elizabeth Angus, et al.
Clinical Kidney Journal|January 15, 2014
Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of <i>CD46</i> treated with eculizumabRodney D Gilbert, Louise K Stanley, Darren J Fowler, et al.
Kidney International|August 3, 2012
Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulationDanielle Paixão-Cavalcante, Margarita López-Trascasa, Lillemor Skattum, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 3, 2010
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotypeMarina Noris, Jessica Caprioli, Elena Bresin, et al.
Kidney International|July 29, 2017
Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and IrelandVicky Brocklebank, Sally Johnson, Thomas P Sheerin, et al.
Pageof 1